Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI311 extension study in thyroid eye disease
CTR20232896Phase 3Completed
- Sponsor
- InnoCare Pharma
- Start
- Sep 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of sycume in Graves Orbitopathy (GO) (2 arms), sponsored by InnoCare Pharma. Started Sep 2023; status: completed.
02
Drugs
sycume
03
Conditions
Graves Orbitopathy (GO)
Beyond the preview
Go deeper on CTR20232896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232896.